VERVE THERAPEUTICS INC (VERV) Stock Income Statement
NASDAQ:VERV - Nasdaq - US92539P1012 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 59.61M | 32.33M | 11.76M | 1.94M | 0.00 | |||
| Operating Expenses | 268.06M | 260.99M | 234.88M | 167.63M | 87.07M | |||
| Research and Development | 210.43M | 204.35M | 184.95M | 130.10M | 68.20M | |||
| Selling, General, and Administrative Expenses | 57.64M | 56.65M | 49.94M | 37.53M | 18.87M | |||
| Operating Income | -208.45M | -228.66M | -223.12M | -165.69M | -87.07M | |||
| Interest Income/Expense | 26.09M | 28.76M | 23.17M | 6.87M | 140.00K | |||
| Other Income/Expense | 1.68M | 1.54M | 165.00K | 1.49M | -33.39M | |||
| Income Before Taxes | -180.68M | -198.36M | -199.79M | -157.33M | -120.31M | |||
| Income Tax | 322.00K | 349.00K | 275.00K | 50.00K | N/A | |||
| Net Income | -181.01M | -198.71M | -200.07M | -157.39M | -120.31M | |||
| EBITDA | -201.62M | -221.91M | -217.67M | -162.89M | -85.53M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.11 | -2.35 | -3.12 | -2.91 | -2.48 | |||
| Non GAAP EPS | -2.11 | -2.35 | -3.12 | -2.92 | N/A | |||
| Statistics | ||||||||
| Profit Margin | -303.64% | -614.59% | -1701.55% | -8112.89% | N/A | |||
| Operating Profit Margin | -349.68% | -707.23% | -1897.64% | -8540.72% | N/A | |||
All data in USD